Avalanche Biotechnologies (AAVL) Misses Q1 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Avalanche Biotechnologies, Inc. Reports First Quarter 2016 Financial Results
May 6, 2016 7:00 AM EDTMENLO PARK, Calif., May 06, 2016 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq: AAVL), a gene therapy company committed to discovering and developing novel medicines for patients suffering from diseases with few or burdensome treatment options, today reported financial results for the quarter ended March 31, 2016.
With the announcement of our proposed transaction with Annapurna Therapeutics, the first quarter of 2016 marked a new direction for Avalanche. Our development plans have expanded to include gene therapy programs targeting difficult to treat orphan diseases, said president and chief executive officer of Avalanche, Paul B. Cleveland. We... More
